Business
Endonovo Therapeutics Begins Process For Medical Reimbursements
Endonovo Therapeutics Begins Process For Medical Reimbursements.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n Los Angeles, CA, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\") today announced undertaking initial steps for obtaining medical reimbursements for their FDA-cleared SofPulse® device. Endonovo considers plans to pursue reimbursement for SofPulse® in the United States-market in connection with American Health Insurance Plans (AHIP) and Centers for Medicare & Medicaid Services (CMS) programs is the best initial path moving forward. Endonovo Therapeutics CEO Alan Collier stated, “Adding medical reimbursement for SofPulse® in the US surgical market can positively effect accelerating our sales growth and market adoption. We are pleased with our present market acceptance of SofPulse® by medical professionals who look to provide more effective treatments for postoperative pain and edema.” Collier continues, “Our initial reimbursement plans are to pursue AHIP because it is the largest and most active national association for healthcare coverage companies and CMS programs as they control nearly all government related healthcare payments. AHIP and CMS have created and are mandating the use of Pain Management Plans, which encourage new technologies to address pain management and reduce opioid use. We believe working with insurance companies, in connection with AHIP and CMS, will be the best plan moving forward to ensure approval and reimbursement for the use of the SofPulse® based upon the proven effectiveness of SofPulse®. We are actively pursuing medical reimbursement at this time to make the SofPulse® therapy available and fully reimbursable as an in-patient and out-patient hospital service.” Mr. Collier continued, “SofPulse® has proven to be an effective postoperative pain and edema reduction treatment and because it is a drug-free treatment helping to combat the prescription opioid crisis gripping the US. We have positioned SofPuse® to provide a necessary and safe treatments to surgical patients, while assisting payors and providers to comply with new regulations as an alternative to opioids for pain management.” About Endonovo Therapeutics Inc. Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticals® therapeutic devices. The Company's current ...